Literature DB >> 9776278

FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors.

T Higashi1, N Tamaki, T Torizuka, Y Nakamoto, H Sakahara, T Kimura, T Honda, T Inokuma, S Katsushima, G Ohshio, M Imamura, J Konishi.   

Abstract

UNLABELLED: We previously reported that grading of GLUT-1 glucose transporter expression was related closely to FDG accumulation in FDG PET in human cancers. But in this strong GLUT-1 expression group, there was an enormous range of standardized uptake values (SUVs) within them.
METHODS: To evaluate other factors determining the FDG PET uptake, FDG PET was performed in 36 preoperative patients (mean age 62.0 yr) suspected of having pancreatic tumors, including 33 malignant and 3 benign neoplastic tumors. FDG uptake at 50 min after injection of 185 MBq 18F-FDG with > 5 hr fasting condition was semiquantitatively analyzed as SUVs. The GLUT-1 expression was studied by immunohistochemistry of paraffin sections from these tumors after the operation using the antiGLUT-1 antibody. The number of tumor cells within a 5- x 5-mm square was counted manually using x200 magnification photographs and was graded immunohistochemically as strong, weak or negative.
RESULTS: In all 36 cases there were 3 cases of GLUT-1 negative, 8 of GLUT-1 weak positive and 25 of GLUT-1 strong positive. In all cases, the total number of tumor cells had no significant value for SUVs. Among 33 GLUT-1 positive cases, the number of GLUT-1 positive tumor cells correlated significantly with SUVs (p < 0.01). Only in 25 strong grade cases, the number of GLUT-1 strong positive tumor cells had a more significant value for SUVs (p < 0.005). Computational multivariate analysis using multiple regression for SUVs was performed evaluating the five variables as follows: tumor size, GLUT-1 immunohistochemical grading, number of total tumor cells, number of total GLUT-1 positive tumor cells and number of GLUT-1 strong positive cells. This analysis revealed that only the variable, the number of GLUT-1 strong positive cells, had a significant regression coefficient for SUVs (standard regression coefficient = 0.855, p < 0.0001).
CONCLUSION: These data indicate that GLUT-1 expression plays an essential role in higher FDG accumulation in pancreatic tumor FDG PET, and the cellularity has a significant influence on SUVs only in the condition of GLUT-1 strong positive expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776278

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  33 in total

1.  Measurement of SUVmax plus ADCmin of the primary tumour is a predictor of prognosis in patients with cervical cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Junichi Kodama; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-11-10       Impact factor: 9.236

2.  FOXM1 promotes the warburg effect and pancreatic cancer progression via transactivation of LDHA expression.

Authors:  Jiujie Cui; Min Shi; Dacheng Xie; Daoyan Wei; Zhiliang Jia; Shaojiang Zheng; Yong Gao; Suyun Huang; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-03-14       Impact factor: 12.531

Review 3.  The Warburg effect: evolving interpretations of an established concept.

Authors:  Xiaozhuo Chen; Yanrong Qian; Shiyong Wu
Journal:  Free Radic Biol Med       Date:  2014-09-30       Impact factor: 7.376

4.  GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis.

Authors:  Olca Basturk; Rajendra Singh; Ecmel Kaygusuz; Serdar Balci; Nevra Dursun; Nil Culhaci; N Volkan Adsay
Journal:  Pancreas       Date:  2011-03       Impact factor: 3.327

5.  Functional properties and genomics of glucose transporters.

Authors:  Feng-Qi Zhao; Aileen F Keating
Journal:  Curr Genomics       Date:  2007-04       Impact factor: 2.236

6.  Value of fluorodeoxyglucose positron emission tomography before radiotherapy for head and neck cancer: does the standardized uptake value predict treatment outcome?

Authors:  Keishiro Suzuki; Takeshi Nishioka; Akihiro Homma; Kazuhiko Tsuchiya; Motoaki Yasuda; Hidefumi Aoyama; Rikiya Onimaru; Nagara Tamaki; Hiroki Shirato
Journal:  Jpn J Radiol       Date:  2009-07-22       Impact factor: 2.374

7.  Proliferation-dependent changes in amino acid transport and glucose metabolism in glioma cell lines.

Authors:  Toshio Sasajima; Tadashi Miyagawa; Takamitsu Oku; Juri G Gelovani; Ronald Finn; Ronald Blasberg
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-13       Impact factor: 9.236

8.  The preoperative SUVmax is superior to ADCmin of the primary tumour as a predictor of disease recurrence and survival in patients with endometrial cancer.

Authors:  Keiichiro Nakamura; Ikuo Joja; Chikako Fukushima; Tomoko Haruma; Chiaki Hayashi; Tomoyuki Kusumoto; Noriko Seki; Atsushi Hongo; Yuji Hiramatsu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-12       Impact factor: 9.236

9.  Successful left hemihepatectomy and perioperative management of a patient with biliary cystadenocarcinoma, complicated with MELAS syndrome: report of a case.

Authors:  Ayami Ohno; Akira Mori; Ryuichiro Doi; Yoshikuni Yonenaga; Noboru Asano; Shinji Uemoto
Journal:  Surg Today       Date:  2010-08-26       Impact factor: 2.549

10.  Epithelial and mesenchymal tumor compartments exhibit in vivo complementary patterns of vascular perfusion and glucose metabolism.

Authors:  Mirco Galiè; Paolo Farace; Cristina Nanni; Antonello Spinelli; Elena Nicolato; Federico Boschi; Paolo Magnani; Silvia Trespidi; Valentina Ambrosini; Stefano Fanti; Flavia Merigo; Francesco Osculati; Pasquina Marzola; Andrea Sbarbati
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.